Ludwig Maximilian University of Munich is a public research university located in Munich, Germany. The University of Munich is Germany's sixth-oldest university in continuous operation.

During the past decade, Ludwig-Maximilians-Universität München conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 10 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 6 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ludwig-Maximilians-Universität München" #1 sponsor was "Pfizer" with 3 trials, followed by "Genentech, Inc." with 2 trials sponsored, "German CLL Study Group" with 2 trials sponsored, "Ludwig-Maximilians - University of Munich" with 2 trials sponsored and "Lux Biosciences, Inc." with 2 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ludwig-Maximilians-Universität München" #1 collaborator was "German Research Foundation" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "A.O. Ospedale Papa Giovanni XXIII" with 1 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Accelopment AG" with 1 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Ludwig-Maximilians-Universität München" are "Alzheimer's Disease" (3 trials), "Smoking Cessation" (3 trials), "Pulmonary Arterial Hypertension" (2 trials), "ALK-positive Advanced NSCLC" (1 trials) and "Acromegaly" (1 trials). Many other conditions were trialed in "Ludwig-Maximilians-Universität München" in a lesser frequency.

Most popular intervention types in "Ludwig-Maximilians-Universität München" are "Drug" (26 trials), "Other" (8 trials), "Biological" (7 trials), "Procedure" (4 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Bendamustine" (2 trials), "LX201" (2 trials), "Obinutuzumab" (2 trials) and "Venetoclax" (2 trials). Other intervention names were less common.

The vast majority of trials in "Ludwig-Maximilians-Universität München" are 40 trials for "All" genders.

Currently, there are NaN active trials in "Ludwig-Maximilians-Universität München". undefined are not yet recruiting, 4 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Ludwig-Maximilians-Universität München, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Ludwig-Maximilians-Universität München, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 6 trials that are defined as “Not Applicable".